Home | Business News | Browse by Publication | B | Biotech Business

ICAGEN COMPLETES ENROLLMENT IN PHASE II ALERGEN ASTHMA TRIAL.

Publication: Biotech Business
Publication Date: 01-JUN-09
Format: Online
Delivery: Immediate Online Access
Full Article Title: ICAGEN COMPLETES ENROLLMENT IN PHASE II ALERGEN ASTHMA TRIAL.(Clinical report)

Article Excerpt
Icagen, Inc. (Nasdaq:ICGN), Research Triangle Park. N.C. has reported the completion of enrollment in the company's Phase II proof-of-concept study of senicapoc in patients with allergic asthma. Initial results from this study are expected during the second half of this year.

As previously reported, the allergen challenge trial is a double-blind, placebo-controlled, parallel group study that is designed to assess the safety and efficacy of senicapoc administered orally on pulmonary function in patients with allergic asthma following exposure to a known antigen. Approximately 30 patients at two research centers in the United Kingdom were randomized in...

Access Full Article, Compliments of Goliath

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from Biotech Business
WAFERGEN/DUKE UNIV. TO USE SMARTCHIP FOR SNP VALIDATION., June 01, 2009

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.